Compare Merck & Co., Inc. (MRK) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Omnicom Group Inc. — how do they compare? Merck & Co., Inc. trades at $133.08 (market cap $321.77B), while Omnicom Group Inc. trades at $85.24 (market cap $23.58B). The key difference: Merck & Co., Inc. is far larger — about 13.6× Omnicom Group Inc.'s market cap, and Omnicom Group Inc. pays the higher dividend (3.72%). Which is the better fit depends on your goals.
| MRK | OMC | |
|---|---|---|
Market Cap | $321.77B | $23.58B |
Sector | Health | Media |
52-Week High | $131.84 | $86.22 |
52-Week Low | $77.60 | $67.27 |
Enterprise Value | $368.53B | $31.66B |
Dividend Yield | 2.61% | 3.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Omnicom Group (OMC) trades at $84.65, down 0.69% on the day, with a bullish technical outlook per moving averages but mixed oscillators. Recent Q2 2026 earnings beat expectations with $2.65 EPS, driven by 6.1% organic revenue growth and margin expansion post-Interpublic acquisition. The company maintains a 4% dividend yield and active buybacks, though high P/E of 232.3 reflects net income volatility.
Outlook is positive with analyst consensus target of $107.00 (27% upside), but risks include integration costs, debt increase, and competitive pressures. The stock offers value from synergy realization and AI-driven growth initiatives, yet investors must monitor execution on cost savings and organic growth sustainability amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
